UC Davis Health Clinical Studies

Experimental Carboplatin & Paclitaxel With or Without Ramucirumab For Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this study is to compare any good and bad effects of using experimental ramucirumab. It will be given along with the usual chemotherapy combination (carboplatin and paclitaxel). Ramucirumab is FDA-approved for non-small cell lung cancer but not for thymic cancer. Ramucirumab in combination with carboplatin and paclitaxel is considered experimental. Ramucirumab is a monoclonal antibody. It is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Ramucirumab targets the vascular endothelial growth factor receptor 2 (VEGFR 2). VEGFR2 is an important molecule that supports the growth of blood vessels by a process called angiogenesis. Growth of these blood vessels can feed tumors and cause them to grow. Ramucirumab blocks VEGFR2 and may prevent angiogenesis in advance thymic tumor patients. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the study approach should extend the amount of time you are cancer-free compared to the usual approach. This chemotherapy combination, carboplatin and paclitaxel, has already been FDA-approved.

Drug study, Phase 2
Any, age 18 years or older

A Study of the Experimental Combination of Axitinib and Nivolumab For Unresectable or Metastatic Renal Cell Carcinoma

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

In this study, we are interested in learning more about how to treat tRCC. To do this, we will test 2 drugs (axinitib and nivolumab) given alone or given together. The drugs axitinib and nivolumab have been used to treat adults and children with different types of cancer, including RCC. Axitinib is a chemotherapy drug that works by stopping the growth of new blood vessels to cancer cells. If left untreated, these feed the cancer cells and allow them to grow. Nivolumab is an immunotherapy that works by helping the body’s immune system (your body’s own defense system) to recognize and attack the cancer cells. Both axitinib and nivolumab have been approved by the FDA for treating RCC. However, using these 2 drugs together is considered experimental. Also, this will be the first formal study of treatments specifically for tRCC. We would like to know if using these drugs alone or together for the treatment of tRCC will be well-tolerated in subjects. Subjects are people who are agree to take part in this study. The overall goal of this study is to find out what effects, good and/or bad, axitinib and nivolumab have on subjects with tRCC when the drugs are given alone or in combination.

Drug study, Phase 2
Any, age 1 years or older

Experimental Standard Systemic Therapy With or Without Surgery or Radiation For Metastatic Prostate Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is being done to test if we can lower the chance of your prostate cancer growing or spreading. We will test adding either prostate removal surgery or radiation therapy to standard treatment. We hope to find out if this will be better or worse than the usual approach for your prostate cancer. This study will compare the effects of adding either prostate removal surgery or radiation therapy to standard systemic therapy (SST). SST is used to treat prostate cancer. Standard systemic therapy includes Androgen Deprivation Therapy (ADT). It is given with or without the use of chemotherapy. ADT is an antihormone therapy whose main use is in treating prostate cancer. The combination of SST and surgery or radiation therapy is considered experimental.

Drug study, Phase 3
Male, age 18 years or older

A Study of the Experimental Combination of Radiation Therapy and Olaparib For Inflammatory Breast Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this study is to test adding the study drug (olaparib) to standard treatment. The addition of olaparib to standard treatment may or may not prevent your cancer from returning. This study will help study doctors learn if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the life of patients. The drug olaparib is approved by the FDA for use in other cancers. Olaparib is not approved for inflammatory breast cancer and is considered experimental in this study.

Drug study, Phase 2
Any, age 18 years or older

Experimental Combination of Olaparib and Radium-223 For Metastatic Castration-Resistant Prostate Cancer That Has Spread

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is for patients with metastatic castration resistant prostate cancer. In this study, we hope to learn if we can lower the chance of your prostate cancer growing or spreading. We will test the addition of the experimental drug, olaparib, to usual treatment with radium-223. We are doing this study because we want to find out if this approach is better or worse than the usual approach. The usual approach is defined as care most people get for metastatic castration resistant prostate cancer. The usual approach for patients who are not in a study is treatment with chemotherapy or hormone therapy. Sometimes, combinations of these treatments are used. Additional available options include radiation therapy for some individuals. Your doctor can explain which treatment may be best for you. These treatments can reduce symptoms and may stop the tumor from growing for a few months or longer.

Other study, Phase [/1/,/ /2/]
Male, age 18 years or older

Experimental Combination of Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel For Advanced Biliary Tract Cancers

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

Biliary cancer is a form of cancer that develops in the bile duct system. This system connects the liver, gallbladder, and small intestine. The biliary ducts move bile, a fluid that helps digest fats, to the small intestine. The purpose of this study is to compare the effects of an experimental combination treatment. I twill be used to treat newly Diagnosed, Advanced Biliary Tract Cancers. The drug nab-paclitaxel will be added to standard treatment with the drugs cisplatin and gemcitabine. This treatment will be compared to treatment with cisplatin and gemcitabine alone. Nabpaclitaxel is an FDA-approved drug for other diseases. It is experimental in this study. The addition of the study drug nab-paclitaxel could shrink your cancer. It could also cause side effects. This study will help the study team learn whether this different approach is better, the same, or worse than standard treatment. In this study, you will get either: - cisplatin and gemcitabine, or - nab-paclitaxel with cisplatin and gemcitabine.

Drug study, Phase 3
Any, age 18 years or older

Experimental Study of a New Drug Combination - Copanlisib and Fulvestrant - in Postmenopausal Women With Advanced Breast Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this study is to compare any good and bad effects of using a specific drug, copanlisib. It will be given along with standard therapy with fulvestrant for advanced breast cancer. The addition of copanlisib to the usual therapy of fulvestrant alone could shrink your cancer/prevent it from returning. It could also cause side effects. The genetic make up of your breast cancer will be important to know before you start treatment in the trial. If you have a protein called PI3K or PTEN, copanlisib may work better when given with fulvestrant to block cancer cell growth. PI3K and PTEN are often altered (or mutated) in cancer cells. If you do not have PI3K or PTEN alterations in your tumor you may still benefit from this therapy. Researchers hope to learn if tumor genetic information is important in predicting if your cancer will respond to fulvestrant and copanlisib. This study will allow researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of copanlisib should shrink breast tumors in about 1 out of every 3 patients treated on this study. Copanlisib is already FDA approved for use in follicular lymphoma. It is usually not used for the treatment of breast cancer and is considered experimental in this study.

Drug study, Phase [/1/,/ /2/]
Female, age 18 years or older
Loading